The Rheumatoid Arthritis Market competitiveness is intensifying as established players and emerging biotech firms race to bring novel therapies to patients. With AbbVie holding the most dominant position built on Humira and upadacitinib, and Pfizer maintaining a strong presence through Xeljanz and Enbrel, competitive positioning strategies are evolving rapidly. The market benefits from a...